US medtech company acquires digital health start-up mementor

Mementor develops digital medical products for various indications. With somnio, mementor operates a digital health application (DiGA) for the treatment of insomnia. Only effective techniques from medical sleep research are used in the “app on prescription” somnio. The company was founded in Switzerland in 2014 by Dr. Noah Lorenz, Alexander Rötger, Jan Kühni and Daniel Rotzetter. Since 2020, the health tech company has been based in Leipzig.

Somnio is Germany’s first and only permanently approved Digital Health Application (DiGA) in the field of sleep medicine and thus eligible for reimbursement in Germany. All German statutory and many private health insurance companies cover the patients costs for somnio upon presentation of a prescription.

Mementor will be integrated into ResMed in Germany as a separate business segment and will serve as a platform for further developments in the field of digital health. The business segment will be co-led by mementor co-founder and CEO Dr. Noah Lorenz and Katherina Jekerle, who was previously ResMed Germany’s senior marketing director and member of the German leadership team.

Based in San Diego, ResMed employs approximately 8,000 people and sell our products in over 140 countries through a combination of wholly owned subsidiaries and independent distributors. The company reported sales of close to $900 million in the first quarter of 2022. ResMed focusses in digital health technologies and cloud-connected medical devices for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. Its comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.

(Press release / SK)
Picture: Fotolia / Leszek Glasner